Literature DB >> 19751987

Characterization of an MPS I-H knock-in mouse that carries a nonsense mutation analogous to the human IDUA-W402X mutation.

Dan Wang1, Charu Shukla, Xiaoli Liu, Trenton R Schoeb, Lorne A Clarke, David M Bedwell, Kim M Keeling.   

Abstract

Here we report the characterization of a knock-in mouse model for the autosomal recessive disorder mucopolysaccharidosis type I-Hurler (MPS I-H), also known as Hurler syndrome. MPS I-H is the most severe form of alpha-l-iduronidase deficiency. alpha-l-iduronidase (encoded by the IDUA gene) is a lysosomal enzyme that participates in the degradation of dermatan sulfate and heparan sulfate. Using gene replacement methodology, a nucleotide change was introduced into the mouse Idua locus that resulted in a nonsense mutation at codon W392. The Idua-W392X mutation is analogous to the human IDUA-W402X mutation commonly found in MPS I-H patients. We found that the phenotype in homozygous Idua-W392X mice closely correlated with the human MPS I-H disease. Homozygous W392X mice showed no detectable alpha-l-iduronidase activity. We observed a defect in GAG degradation as evidenced by an increase in sulfated GAGs excreted in the urine and stored in multiple tissues. Histology and electron microscopy also revealed evidence of GAG storage in all tissues examined. Additional assessment revealed bone abnormalities and altered metabolism within the Idua-W392X mouse. This new mouse will provide an important tool to investigate therapeutic approaches for MPS I-H that cannot be addressed using current MPS I-H animal models.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19751987      PMCID: PMC2795040          DOI: 10.1016/j.ymgme.2009.08.002

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  50 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Effectiveness of a gentamicin dosing protocol based on postconceptional age: comparison to published neonatal guidelines.

Authors:  A M Lopez-Samblas; C L Torres; H Wang; W J Feuer; R N Goldberg
Journal:  Ann Pharmacother       Date:  1992-04       Impact factor: 3.154

3.  Hexosaminidase assays.

Authors:  Michaela Wendeler; Konrad Sandhoff
Journal:  Glycoconj J       Date:  2009-11       Impact factor: 2.916

4.  Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I.

Authors:  E D Kakkis; M F McEntee; A Schmidtchen; E F Neufeld; D A Ward; R E Gompf; S Kania; C Bedolla; S L Chien; R M Shull
Journal:  Biochem Mol Med       Date:  1996-08

5.  Morphologic and biochemical studies of canine mucopolysaccharidosis I.

Authors:  R M Shull; R G Helman; E Spellacy; G Constantopoulos; R J Munger; E F Neufeld
Journal:  Am J Pathol       Date:  1984-03       Impact factor: 4.307

6.  Architecture of the canine IDUA gene and mutation underlying canine mucopolysaccharidosis I.

Authors:  K P Menon; P T Tieu; E F Neufeld
Journal:  Genomics       Date:  1992-11       Impact factor: 5.736

7.  Characterization of an immunodeficient mouse model of mucopolysaccharidosis type I suitable for preclinical testing of human stem cell and gene therapy.

Authors:  Mayra F Garcia-Rivera; Leah E Colvin-Wanshura; Matthew S Nelson; Zhenhong Nan; Shaukat A Khan; Tyson B Rogers; Indrani Maitra; Walter C Low; Pankaj Gupta
Journal:  Brain Res Bull       Date:  2007-08-06       Impact factor: 4.077

8.  Lysosomal dysfunction results in altered energy balance.

Authors:  Josh C Woloszynek; Trey Coleman; Clay F Semenkovich; Mark S Sands
Journal:  J Biol Chem       Date:  2007-10-02       Impact factor: 5.157

Review 9.  Molecular genetics of mucopolysaccharidosis type I: diagnostic, clinical, and biological implications.

Authors:  H S Scott; S Bunge; A Gal; L A Clarke; C P Morris; J J Hopwood
Journal:  Hum Mutat       Date:  1995       Impact factor: 4.878

Review 10.  Lysosomal disorders: from storage to cellular damage.

Authors:  Andrea Ballabio; Volkmar Gieselmann
Journal:  Biochim Biophys Acta       Date:  2008-12-08
View more
  29 in total

1.  Morphologic description of male reproductive accessory glands in a mouse model of mucopolysaccharidosis type I (MPS I).

Authors:  Cinthia Castro do Nascimento; Odair Aguiar Junior; Vânia D'Almeida
Journal:  J Mol Histol       Date:  2020-03-11       Impact factor: 2.611

Review 2.  Animal models of human genetic diseases: do they need to be faithful to be useful?

Authors:  Jean-Louis Guénet
Journal:  Mol Genet Genomics       Date:  2011-05-06       Impact factor: 3.291

3.  Long-term nonsense suppression therapy moderates MPS I-H disease progression.

Authors:  Gwen Gunn; Yanying Dai; Ming Du; Valery Belakhov; Jeyakumar Kandasamy; Trenton R Schoeb; Timor Baasov; David M Bedwell; Kim M Keeling
Journal:  Mol Genet Metab       Date:  2013-12-17       Impact factor: 4.797

4.  The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse.

Authors:  Dan Wang; Valery Belakhov; Jeyakumar Kandasamy; Timor Baasov; Su-Chen Li; Yu-Teh Li; David M Bedwell; Kim M Keeling
Journal:  Mol Genet Metab       Date:  2011-10-19       Impact factor: 4.797

5.  Quantitative Trait Locus and Integrative Genomics Revealed Candidate Modifier Genes for Ectopic Mineralization in Mouse Models of Pseudoxanthoma Elasticum.

Authors:  Qiaoli Li; Vivek M Philip; Timothy M Stearns; Jason A Bubier; Benjamin L King; Benjamin E Low; Michael V Wiles; Amir Hossein Saeidian; Beth A Sundberg; Jouni Uitto; John P Sundberg
Journal:  J Invest Dermatol       Date:  2019-06-15       Impact factor: 8.551

6.  Effect of Readthrough Treatment in Fibroblasts of Patients Affected by Lysosomal Diseases Caused by Premature Termination Codons.

Authors:  Leslie Matalonga; Ángela Arias; Frederic Tort; Xènia Ferrer-Cortés; Judit Garcia-Villoria; Maria Josep Coll; Laura Gort; Antonia Ribes
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

Review 7.  Mucopolysaccharidosis type I: current knowledge on its pathophysiological mechanisms.

Authors:  Derbis Campos; Madelyn Monaga
Journal:  Metab Brain Dis       Date:  2012-04-14       Impact factor: 3.584

8.  Identification of IDUA and WNT16 Phosphorylation-Related Non-Synonymous Polymorphisms for Bone Mineral Density in Meta-Analyses of Genome-Wide Association Studies.

Authors:  Tianhua Niu; Ning Liu; Xun Yu; Ming Zhao; Hyung Jin Choi; Paul J Leo; Matthew A Brown; Lei Zhang; Yu-Fang Pei; Hui Shen; Hao He; Xiaoying Fu; Shan Lu; Xiang-Ding Chen; Li-Jun Tan; Tie-Lin Yang; Yan Guo; Nam H Cho; Jie Shen; Yan-Fang Guo; Geoffrey C Nicholson; Richard L Prince; John A Eisman; Graeme Jones; Philip N Sambrook; Qing Tian; Xue-Zhen Zhu; Christopher J Papasian; Emma L Duncan; André G Uitterlinden; Chan Soo Shin; Shuanglin Xiang; Hong-Wen Deng
Journal:  J Bone Miner Res       Date:  2015-09-11       Impact factor: 6.741

9.  Rational Design of RNA Editing Guide Strands: Cytidine Analogs at the Orphan Position.

Authors:  Erin E Doherty; Xander E Wilcox; Lenka van Sint Fiet; Cherie Kemmel; Janne J Turunen; Bart Klein; Dean J Tantillo; Andrew J Fisher; Peter A Beal
Journal:  J Am Chem Soc       Date:  2021-05-03       Impact factor: 15.419

10.  In utero adenine base editing corrects multi-organ pathology in a lethal lysosomal storage disease.

Authors:  Sourav K Bose; Brandon M White; Meghana V Kashyap; Apeksha Dave; Felix R De Bie; Haiying Li; Kshitiz Singh; Pallavi Menon; Tiankun Wang; Shiva Teerdhala; Vishal Swaminathan; Heather A Hartman; Sowmya Jayachandran; Prashant Chandrasekaran; Kiran Musunuru; Rajan Jain; David B Frank; Philip Zoltick; William H Peranteau
Journal:  Nat Commun       Date:  2021-07-13       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.